Search for: "ALLERGAN USA"
Results 21 - 40
of 92
Sort by Relevance
|
Sort by Date
6 Jun 2019, 6:49 am
Teva Pharmaceuticals USA, Inc. [read post]
5 Jun 2019, 2:37 pm
Teva Pharmaceuticals USA, Inc. [read post]
5 Jun 2019, 2:37 pm
Teva Pharmaceuticals USA, Inc. [read post]
30 May 2019, 2:02 pm
USA, Inc., 518 F.3d 1353, 1366(Fed. [read post]
19 Apr 2019, 5:58 am
Teva Pharmaceuticals USA, Inc. [read post]
18 Apr 2019, 1:57 pm
Teva Pharmaceuticals USA, Inc. [read post]
18 Apr 2019, 1:57 pm
Teva Pharmaceuticals USA, Inc. [read post]
15 Apr 2019, 9:23 pm
IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132 (and parallel IPRs filed by Petitioners Teva Pharmaceuticals USA, Inc.... [read post]
15 Apr 2019, 6:09 am
Teva Pharmaceuticals USA Inc.: Allergan & SRMT Cert Petition Questions presented: Whether the Federal Circuit erred in this case, as it did in Acorda Therapeutics, Inc. v. [read post]
18 Mar 2019, 10:57 am
Allergan USA, Inc. v. [read post]
17 Aug 2018, 5:58 am
Companies that invent in that area include: Abbot Allergan AMO Development, LLC Applied Medical Resources Corp. [read post]
8 Aug 2018, 11:15 pm
However, Allergan’s insurance policy may never pay out – in late July, the Court of Appeals for the Federal Circuit rejected the applicability of tribal sovereign immunity to IPR. [read post]
23 Jul 2018, 2:38 pm
Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AKORN, Inc. [read post]
23 Jul 2018, 12:05 pm
Teva Pharmaceuticals USA, Inc., et al., No. 17-1229. [read post]
20 Jul 2018, 11:44 pm
TevaPharmaceuticals USA, Inc., and Akorn, Inc. [read post]
19 Oct 2017, 2:17 pm
TEVA Pharmaceuticals USA, INC. [read post]
19 Oct 2017, 2:17 pm
TEVA Pharmaceuticals USA, INC. [read post]
19 Oct 2017, 10:29 am
Teva Pharmaceuticals USA, Inc. et al, Case No. 2:15-cv-1455-WCB (EDTX October 16, 2017 Order), a Federal District Court recently invalidated several patents covering Allergan’s dry-eye drug Restasis. [read post]
19 Oct 2017, 10:29 am
Teva Pharmaceuticals USA, Inc. et al, Case No. 2:15-cv-1455-WCB (EDTX October 16, 2017 Order), a Federal District Court recently invalidated several patents covering Allergan’s dry-eye drug Restasis. [read post]